Vanguard Capital Management’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
Other funds holding OVID
Vanguard Capital Management's OVID Position: Q3 2026 in Review
Vanguard Capital Management increased its Ovid Therapeutics (OVID) stake by 0.88% in Q3 2026, buying an estimated $179K and bringing the position to 7,828,361 shares worth $19.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2411.
Vanguard Capital Management first reported a position in OVID in Q1 2026 and has held it in 3 quarters since. The position peaked at $20.9M in Q2 2026. 129 funds tracked by Wall St. Rank hold OVID as of Q3 2026.
- Vanguard Capital Management held 7,828,361 shares of Ovid Therapeutics worth $19.5M as of Q3 2026.
- Vanguard Capital Management bought 68,247 Ovid Therapeutics shares in Q3 2026, an estimated $179K.
- Ovid Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2411 holding.
- Vanguard Capital Management first reported a position in Ovid Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Ovid Therapeutics position peaked at $20.9M in Q2 2026.
- 129 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.